Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CGP 37391; CMX 001 - CorMedix; CP 020; CP 20; CRMD-001; Ferriprox; Ferriprox Oral Solution; Kelfer; L1

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Royal Free and University College Medical School
  • Developer Apotex; Centre Hospitalier Univeristaire De Lille; CorMedix
  • Class Antianaemics; Antineoplastics; Antirheumatics; Pyridones; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase III Pantothenate kinase-associated neurodegeneration
  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease
  • No development reported Friedreich's ataxia; HIV infections
  • Discontinued Kidney disorders

Most Recent Events

  • 14 Jan 2019 ApoPharma plans the TWICE phase II trial for Iron overload in February 2019 (NCT03802916)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in HIV-infections(First-line therapy) in South Africa (IV, Infusion)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Iron-overload(In volunteers) in Canada (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top